Loading
A phase 2 trial of trilaciclib and lurbinectedin in lung cancer, run by UNC Lineberger Comprehensive Cancer Center, now recruiting.
Study of Trilaciclib and Lurbinectidin is a phase 2, interventional study registered as NCT05578326 by UNC Lineberger Comprehensive Cancer Center, with a registry enrolment figure of 30 participants, started 2022-10-12 and due to reach its primary completion in 2026-12-25. Interventions recorded: Trilaciclib; Lurbinectedin. Conditions listed: Lung Cancer; Small-cell Lung Cancer. Primary outcome: The proportion of grade 4 neutropenia; The duration of grade 4 neutropenia. Sites: United States. No results are recorded here; the registry entry is the source.
Shares Lurbinectedin, Lung cancer trials open today (registry snapshot), Small-cell lung cancer, Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Trilaciclib, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Trilaciclib, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Lurbinectedin, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Small-cell lung cancer and the tag lung-deep-dive.